CYSTISTAT

País: Espanha

Língua: espanhol

Origem: myHealthbox

Ingredientes ativos:

hialuronato sódico

Disponível em:

LABORATORIOS RUBIO, S.A.

Unidades em pacote:

1 vial de 50 ml con 40 mg de hialuronato sódico

Fabricado por:

Mylan Institutional, Inverin, Co. Galway, Ireland.

Indicações terapêuticas:

El deterioro de esta capa de GAG del epitelio de la vejiga puede anular su función de barrera y permitir la adherencia de bacterias, microcristales, proteínas e iones, o el tránsito de residuos solubles iónicos y no iónicos como la urea a través del epitelio. CYSTISTAT® ha demostrado ser útil en el tratamiento de: Cistitis rádica, Cistitis infecciosa, Cistitis intersticial, Cistitis hemorrágica.

Resumo do produto:

CYSTISTAT® es una solución estéril de Hialuronato Sódico para la reposición temporal de la capa de glicosaminoglicanos (GAG) de la vejiga urinaria.

Características técnicas

STERILE SODIUM HYALURONATE SOLUTION
For temporary replacement of the glycosaminoglycan (GAG) layer in
the bladder.
DESCRIPTION: The glycosaminoglycan (GAG) layer on the luminal
surface of the bladder wall is believed to provide a protective bar-
rier against microorganisms, carcinogens, crystals and other agents
present in the urine and has been identified as the primary defense
mechanism in protecting the transitional epithelium from urinary irri-
tants.
1
Deficiencies in this GAG layer of the bladder epithelium may
destroy its barrier function and allow the adherence of bacteria, mi-
crocrystals, proteins and ions, or the movement of ionic and nonionic
solute residues (i.e. urea) across the epithelium.
2
CYSTISTAT
®
has
been developed to temporarily replenish the deficient GAG layer on
the bladder epithelium. The active substance is a highly purified
sodium
salt of hyaluronic acid.
EACH CYSTISTAT
® VIAL CONTAINS: 40 mg sodium hyaluronate.
DIRECTIONS: Instill the entire volume of this solution into the
bladder
after any residual urine has been removed. Discard any unused portion.
For best results CYSTISTAT
®
should be retained in the bladder for as
long as possible (a minimum of 30 minutes).
There is evidence that the GAG layer of the bladder is deficient in
cysti-
tis. This deficiency contributes to the clinical symptoms
2
in the diseases
such as interstitial cystitis,
3
cystitis caused by infections, trauma, uro-
lithiasis, urinary retention, neoplasia and radiation induced
cystitis.
4
To
alleviate cystitis associated with these conditions, it is recommended
that CYSTISTAT
®
be instilled into the bladder each week for 4-12
treatments and then monthly until symptoms resolve. The attending
physician, urologist or radiologist should direct any prophylactic use
of
CYSTISTAT
®
.
PRECAUTION: Do not administer to patients with known hypersensi-
tivity reactions. Discontinue use if adverse reactions are
experienced.
As no clinical evidence is available on the use of Hyaluronic Acid in
children, pregnant and lacta